In 157 patients with stage II-III triple-negative breast cancer, adding low-dose pembrolizumab to neoadjuvant chemotherapy raised pathological complete response from 40.5% to 53.8% (one-sided P=0.047). Grade ≥3 toxicity: 50% vs 59.5%.
RCTn = 157
Arora et al. A phase II, randomized, open-label study to evaluate low-dose pembrolizumab plus chemotherapy versus chemotherapy as neoadjuvant therapy for localized triple-negative breast cancer (TNBC) (PLANeT trial-Pembrolizumab Low dose in Addition to NACT in TNBC)